Table 3.
The PCR Cycle for ENOSF1 Variants
| Polymorphism | Genotypes | No. of patients | Treatment | p value | |
|---|---|---|---|---|---|
| (n=100) | Responders | non-responders | |||
| TS 5ꞌ UTR | 2R2R | 25 (25%) | 14 (56%) | 11 (44%) | |
| 2R3R | 54 (54%) | 36 (66.7%) | 18 (33.3%) | ||
| 3R3R | 21 (21%) | 7 (33.3%) | 14 (66.7%) | ||
| TS 5ꞌ UTR SNP | 3RC3RC, 2R3RC | 50 (50%) | 29 (58%) | 21 (42%) | 0.29 |
| 3RG3RG, 2R3RG | 23 (23%) | 9 (39.1%) | 14 (60.9%) | ||
| 3RC3RG | 2 (2%) | 0 (0%) | 2 (100%) | ||
| TS 3ꞌ UTR | del6/del6 | 3 (3%) | 3 (100%) | 0 (0%) | 0.26 |
| del6/ins6 | 81 (81%) | 47 (58%) | 34 (42%) | ||
| ins6/ins6 | 16 (16%) | 7 (43.8%) | 9 (56.3%) | ||
| ENOSF1 (rs2612091) | AA | 29 (29%) | 15 (51.7%) | 14 (48.3%) | |
| AG | 48 (48%) | 23 (47.9%) | 25 (52.1%) | ||
| GG | 23 (23%) | 19 (82.6%) | 4 (17.4%) | ||
| ENOSF1 (rs2741171) | AA | 16 (16%) | 11 (68.8%) | 5 (31.3%) | 0.065 |
| AG | 36 (36%) | 15 (41.7%) | 21 (58.3%) | ||
| GG | 48 (48%) | 31 (64.6%) | 17 (35.4%) | ||
* The χ2 test was used for the correlation study; ** The Monte-Carlo test used for TS 5ꞌ UTR SNP and TS 3ꞌ UTR polymorphisms; * A p-value < 0.05 was considered as significant